• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

eye disease

Close-up of human eye
Biotech

Opus sets sights on FDA talks after posting gene therapy data

Opus Genetics shared data on its gene therapy in kids with an ultrarare eye disease, setting the biotech up to talk to the FDA about the next steps.
Nick Paul Taylor Sep 30, 2025 9:15am
Two fencers spar in a stadium

Eye disease biotech launches with $100M, Roche rival in clinic

Sep 17, 2025 6:30am
Close-up of human eye

Opthea ramps up cuts to 85% of staff, including CEO

Aug 19, 2025 7:35am
eye eyeball eye art

Boehringer inks another eye disease deal, this time with Palatin

Aug 18, 2025 10:30am
pivot change turnaround direction walk away

Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out

Jul 24, 2025 5:00am
eye drops

Cloudbreak plots phase 3 after eye drop passes midstage test

Jul 21, 2025 4:35am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings